Back to results
Not yet recruitingPhase 1Phase 2

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

NCT07139470

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Tianjin Cancer Hospital Airport Hospital

Tianjin, Tianjin Municipality, China

View on ClinicalTrials.gov
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer — TrialFind